CD8 alpha Blocking Peptide for STJ505971 peptide (STJ505746)

SPECIFICATIONS
ImmunogenSynthetic peptide taken within amino acid region 1-50 on human T-cell surface glycoprotein CD8 Alpha chain.
STJ505746-250
🚚 Free UK Delivery on orders over £150
Processing The item has been added
Enquire For Bulk Order
✓ 1-Year Performance Guarantee | SDS & Datasheet Included | Expert Tech Support | Covered by St John's Laboratory Guarantee

General Information

Short DescriptionCD8 alpha Blocking Peptide for STJ505971 is synthetically produced from the 1-50 sequence and is suitable for use in western blot applications.
ApplicationsImmunodepletion/Immunocompetition
NoteSTRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.

Product Properties

FormulationLiquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage InstructionStore at-20°C for long term storage. Avoid freeze-thaw cycles.

Target Information

Gene SymbolCD8A
Gene ID925
Uniprot IDCD8A_HUMAN
ImmunogenSynthetic peptide taken within amino acid region 1-50 on human T-cell surface glycoprotein CD8 Alpha chain.
Immunogen Region1-50
SpecificityThis blocking peptide is recommended for use in combination with CD8 alpha antibody, STJ505971

Additional Info

Post Translational Modifications Palmitoylated, but association with CD8B seems to be more important for the enrichment of CD8A in lipid rafts. O-glycosylated. Phosphorylated in cytotoxic T-lymphocytes (CTLs) following activation.
Function Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.
Peptide Name T-Cell Surface Glycoprotein Cd8 Alpha Chain
T-Lymphocyte Differentiation Antigen T8/Leu-2
Cd Antigen Cd8a
Database Links Reactome: R-HSA-198933
Cellular Localisation Isoform 1: Cell Membrane
Single-Pass Type I Membrane Protein
Cd8a Localizes To Lipid Rafts Only When Associated With Its Partner Cd8b
Isoform 2: Secreted
Alternative Peptide Names T-Cell Surface Glycoprotein Cd8 Alpha Chain protein
T-Lymphocyte Differentiation Antigen T8/Leu-2 protein
Cd Antigen Cd8a protein
CD8A protein
MAL protein

Information sourced from Uniprot.org

Citations

Product Review

Well-cited Academic Publications
KO-Validated 700+ Lines
Technical Support Expert Scientific Team
1-Year Guarantee Antibodies & Proteins